Due to the importance of VMAT2 in controlling the dopamine levels found in the human body, numerous approaches to controlling VMAT2 have been studied toward the treatment of related diseases, such as Parkinson’s disease (PD) [3], Huntington’s disease (HD) [4], and schizophrenia [5]. This evidence concerns the gene SLC18A2 and schizophrenia.